PDGFA was highly expressed in glioma (20.6 ± 16.6 FPKM), lung cancer (9.0 ± 9.0 FPKM), colorectal cancer (7.5 ± 5.5 FPKM), head and neck cancer (7.1 ± 5.4 FPKM), stomach cancer (8.9 ± 6.9 FPKM), liver cancer (6.3 ± 6.9 FPKM), pancreatic cancer (11.1 ± 7.6 FPKM), renal cancer (15.5 ± 14.3 FPKM), urothelial cancer (6.7 ± 7.0 FPKM), prostate cancer (11.8 ± 4.4 FPKM), testis cancer (16.0 ± 18.0 FPKM), breast cancer (16.3 ± 18.0 FPKM), and melanoma (8.9 ± 16.0 FPKM) (Figure 9(c)), while PDGFA in other cancers was less than 3.0 FPKM. Here, PDGFA is linked to prostate carcinoma.